AcelRx Pharmaceuticals(US:ACRX)2026-03-23 12:35Clinical Study Progress - Talphera achieved 50% enrollment in the NEPHRO CRRT clinical study, reaching a milestone of 35 patients[2] - The NEPHRO CRRT study is designed to enroll 70 adult patients and is expected to complete later in 2026[12] Financial Performance - Cash and investments totaled $20.4 million as of December 31, 2025, compared to $8.9 million in 2024[18] - Combined R&D and SG&A expenses for Q4 2025 were $3.5 million, an increase from $3.0 million in Q4 2024[8] - The net loss for Q4 2025 was $3.8 million, or $0.06 per share, compared to a net loss of $1.9 million, or $0.07 per share, in Q4 2024[8] - Total operating expenses for the year ended December 31, 2025, were $13.5 million, down from $15.3 million in 2024[19] - Talphera expects cash operating expenses in the range of $17 million to $18 million for 2026, up from approximately $13 million in 2025[5] Product Development - Talphera's lead product candidate, Niyad, has received Breakthrough Device Designation status from the FDA[9] Investor Relations - The company plans to host a virtual investor and analyst day on March 23, 2026, to provide business updates[1] Financing Activities - The company closed a financing tranche of $4.1 million upon achieving the 35-patient enrollment milestone[8]